Characterization of [ 3H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive

Journal of Neuroscience Methods

Volumn 203, Issue 1, 2012, Pages 19-27

  Zhen, Juan ^a   Ali, Solav ^a   Dutta, Aloke K ^b   Reith, Maarten E A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Binding; CFT; Dixon plot; Dopamine transporter; Mutually exclusive; Nisoxetine; Norepinephrine transporter

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE; DESIPRAMINE; DOPAMINE; DOPAMINE TRANSPORTER; MAZINDOL; NISOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; SODIUM;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; EMBRYO; FEASIBILITY STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

BINDING, COMPETITIVE; COCAINE; FLUOXETINE; HEK293 CELLS; HUMANS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; TRITIUM;

EID: 81555219221     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2011.08.044     Document Type: Article

References (38)

1. 3H]desipramine binding to rat brain tissue: binding to both noradrenaline uptake sites and sites not related to noradrenaline neurons. J. Neurochem. 1989, 52:1099-1106.
2. 3H]nisoxetine autoradiography. Brain Res. 1992, 582:208-214.
3. Beuming T., Kniazeff J., Bergmann M.L., Shi L., Gracia L., Raniszewska K., Newman A.H., Javitch J.A., Weinstein H., Gether U., Loland C.J. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat. Neurosci. 2008, 11:780-789.
4. Bonnet J. Interactions of cations and anions with the binding of uptake blockers to the dopamine transporter. Eur. J. Pharm. 2003, 479:199-212.
5. Bönisch H., Brüss M. The norepinephrine transporter in physiology and disease. Handb. Exp. Pharmacol. 2006, 175:485-524.
6. Bryan-Lluka L.J., Bonisch H., Lewis R.J. chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter. J. Biol. Chem. 2003, 278:40324-40329.
7. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
8. Coyle J.T., Snyder S.H. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J. Pharmacol. Exp. Ther. 1969, 170:221-231.
9. 3H]nomifensine to striatal membranes. Biochem. Pharmacol. 1985, 34:1137-1144.
10. Dutta A.K., Ghosh B., Biswas S., Reith M.E. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action. Eur. J. Pharmacol. 2008, 589:73-79.
11. Eshleman A.J., Carmolli M., Cumbay M., Martens C.R., Neve K.A., Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 1999, 289:877-885.
12. 3H] desipramine binding in rat cerebral cortex. Prog. Neuropsychopharmacol. 1981, 5:553-557.
13. 3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol. Pharmacol. 1984, 26:35-44.
14. Kuhar M.J., McGirr K.M., Hunter R.G., Lambert P.D., Garrett B.E., Carroll F.I. Studies of selected phenyltropanes at monoamine transporters. Drug Alcohol Depend. 1999, 56:9-15.
15. Kurian M.A., Zhen J., Cheng S.-Y., Li Y., Mordekar S.R., Jardine P., Morgan N.V., Meyer E., Tee L., Pasha S., Wassmer E., Heales S.J.R., Gissen P., Reith M.E.A., Maher E.R. Homozygous loss-of-function mutations in the dopamine transporter are associated with infantile parkinsonism-dystonia. J. Clin. Inv. 2009, 119(6):1595-1603.
16. 3H]desipramine binding associated with neuronal norepinephrine uptake sites in rat brain membranes. J. Neurosci. 1982, 2:1515-1525.
17. 3H]WIN 35,428 to the human dopamine transporter. J. Neurochem. 1999, 72:1095-1109.
18. - with the binding of amphetamine, octopamine, and tyramine to the human dopamine transporter. J. Neurochem. 2000, 74:1538-1552.
19. Loland C.J., Granas C., Javitch J.A., Gether U. Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. J. Biol. Chem. 2004, 279:3228-3238.
20. 3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol. Pharmacol. 1989, 36:518-524.
21. Norregaard L., Frederiksen D., Nielsen E.O., Gether U. Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO J. 1998, 17:4266-4273.
22. Pacholczyk T., Blakely R.D., Amara S.G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991, 350:350-354.
23. Paczkowski F.A., Sharpe I.A., Dutertre S., Lewis R.J. chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model. J. Biol. Chem. 2007, 282:17837-17844.
24. Ravna A.W., Sylte I., Dahl S.G. Structure and localisation of drug binding sites on neurotransmitter transporters. J. Mol. Model. 2009, 15(10):1155-1164.
25. Reith M.E.A., Wang L.C., Dutta A.K. Pharmacological profile of radioligand binding to the norepinephrine transporter: instances of poor indication of functional activity. J. Neurosci. Methods 2005, 143:87-94.
26. 125I]RTI-55, in membranes prepared from whole rat brain minus caudate. J. Pharmacol. Exp. Ther. 1995, 274:385-395.
27. Sarker S., Weissensteiner R., Steiner I., Sitte H.H., Ecker G.F., Freissmuth M., Sucic S. The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol. Pharmacol. 2010, 78:1026-1035.
28. 3H-nomifensine binding sites in rat brain. Life Sci. 1985, 36:815-822.
29. Schmitt K.C., Zhen J., Kharkar P., Mishra M., Chen N., Dutta A.K., Reith M.E. Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. J. Neurochem. 2008, 107:928-940.
30. Segel I.H. Chapter Eight: Multiple inhibition analysis. Enzyme Kinetics Behavior and anlysis of rapid equilibrium and steady state Enzyme systems 1975, John Wiley and Sons, Inc., pp 465-505.
31. + dependence, and structure-activity relationship. J. Biol. Chem. 2003, 278:40317-40323.
32. Sucic S., Bryan-Lluka L.J. Roles of transmembrane domain 2 and the first intracellular loop in human noradrenaline transporter function: pharmacological and SCAM analysis. J. Neurochem. 2005, 94:1620-1630.
33. 3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J. Pharmacol. Exp. Ther. 1992, 260:427-436.
34. Tomlinson G. Potential misconceptions arising from the application of enzyme kinetic equations to ligand-receptor systems at equilibrium. Can. J. Physiol. Pharmacol. 1988, 66:342-349.
35. Wang S., Sakamuri S., Enyedy I.J., Kozikowski A.P., Deschaux O., Bandyopadhyay B.C., Tella S.R., Zaman W.A., Johnson K.M. Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. J. Med. Chem. 2000, 43:351-360.
36. + gradient and membrane potential: dopamine versus other substrates. Neuropharmacology 2005, 49:769-779.
37. Zhou Z., Zhen J., Karpowich N.K., Law C.J., Reith M.E., Wang D.N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol. 2009, 16:652-657.
38. Zhu M.Y., Kyle P.B., Hume A.S., Ordway G.A. The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function. Neurochem. Res. 2004, 29:419-427.